Doctors/Physician section


Research-grade over 5% minoxidil restores the vertex of the scalp.

  • Polaris NR-07 and 08 contain 0.5% apple polyphenol to repopulate the frontal hairline.
  • Apple polyphenol conveys free-radical scavenging activity, antioxidative properties, antifungal effects, and antiallergic activity.
  • In vitro, apple polyphenol promotes hair epithelial cell growth at an astounding rate of 300 percent relative to controls.

Polaris NR-07 and 08 restores the hairline using natural apple polyphenol, shown in current studies to increase hair density dramatically.

Polaris NR-07, 08, 09, and Shampoo NR-02 uses minoxidil to arrest hair loss and target hair regrowth on the vertex of the scalp, where male pattern baldness (androgenic alopecia) generally begins. Like so many advances in science, researchers discovered minoxidil’s effects almost by accident. Three decades later, Polaris researchers continue to search for the molecule’s exact mechanism of action.

Through numerous studies, Polaris knows that topical minoxidil shortens the telogen (resting) phase of hair follicles, causing early entry into anagen (growth) phase. It may also prolong anagen and increase follicle size. We know that minoxidil taken orally lowers blood pressure by relaxing vascular smooth muscle through the action of minoxidil sulphate.

Some evidence suggests that minoxidil stimulates hair growth by opening potassium channels. In vitro, its effects on hair follicles and skin include cellular proliferation, inhibition of collagen synthesis, stimulation of vascular endothelial growth factor, and prostaglandin synthesis. While some or all of these effects may pertain to hair growth, their application to the real-world biology of complex hair follicles is still evolving.

Physicians first introduced minoxidil in the 1970s as a treatment for hypertension. As a side effect, they noticed that patients taking the drug orally, including those who were balding, grew new hair. Taking advantage of this property, drug companies of that era developed a topical form to treat androgenetic alopecia in men and subsequently women. A 2% product rolled out in 1986 and a 5% solution in 1993.

Minoxidil has been studied extensively in stump-tailed macaques — primates that develop androgenetic alopecia similar to humans — and is found to prevent hair loss in periadolescent individuals and to promote its regrowth in balding ones. Histological studies revealed that minoxidil caused an increase in the percentage of follicles in anagen phase, a reduction of those in telogen phase, and an increase in hair follicle size.

Studies of humans with male pattern baldness find a gradual shortening of anagen phase and lengthening of the latency period between telogen shedding and new anagen growth. Hairs and their follicles also become miniaturized.

Clinical trials of research-grade minoxidil, as incorporated into Polaris NR-07, all show a remarkably rapid increase in hair growth, measured both by count and by weight. Improvement is evident within six to eight weeks and generally peaks around 12 to 16 weeks. Such speed suggests that minoxidil induces hair follicles into anagen. The increased length of hairs suggests that it also prolongs the duration of anagen. Some studies find an increase in mean hair diameter and follicle size.

Potassium channels >